Mexico has been a very important market for Biocon since 2006, where it has been playing a significant role in enabling access to affordable rh-Insulin.

Insulin Glargine will augment the affordable insulin therapy for diabetes management.
'GALACTUS' by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012.

Biocon's presence in Mexico, over the last eight years, has expanded the insulins market substantially by initiating many more patients onto insulin therapy.

The increasing affordability of Insulin Glargine will now enable Biocon and PiSA to expand this reach further.

The combined market for Insulin Glargine in Mexico is estimated to be in excess of USD 40 million.

Biocon's CMD Dr Kiran Mazumdar-Shaw commented, "....Our Insulin Glargine will now enable access to a basal insulin which will further expand the diabetes management therapy for patients in Mexico."

Currently Biocon has marketing approvals in over 60 countries for rh-Insulin and in over 20 countries for Insulin Glargine.

PiSA's group executive VP Lic. Santiago Alvarez Vega said: "We are extremely excited to partner with Biocon to introduce GALACTUS, the long acting insulin glargine in Mexico, which has a disease prevalence of 12 percent, the second highest in the world. We hope to enable the government to bring down its per capita expenditure on diabetes with the use of this cost effective, high quality biocomparable Insulin Glargine"

Diabetes is a major health risk in Mexico, over 70% of the Mexican population is overweight thus prone to developing diabetes.

With over 9 million cases of diabetes, it poses a huge disease burden for the government with per capita expenditure on diabetes being as high as USD 892.5.